US biotech Moderna (Nasdaq: MRNA), the company that came to the world’s attention and earned billions as a result of its development of an mRNA COVID-19 vaccine, has announced a global health strategy as it looks to the next phase of its growth.
The company is announcing a commitment to expand its global public health portfolio to 15 vaccine programs targeting priority pathogens that threaten global health, with plans to advance these into clinical studies by 2025.
These pathogens have been identified as the biggest public health risks by the World Health Organization and Coalition for Epidemic Preparedness Innovations CEPI
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze